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Abstract
CD160 is a cell surface molecule expressed by most NK cells and approximately 50% of CD8+ cytotoxic T lymphocytes.
Engagement of CD160 by MHC class-I directly triggers a costimulatory signal to TCR-induced proliferation, cytokine
production and cytotoxic effector functions. The role of CD160 in alloimmunity is unknown. Using a newly generated CD160
fusion protein (CD160Ig) we examined the role of the novel costimulatory molecule CD160 in mediating CD4+ or CD8+ T cell
driven allograft rejection. CD160Ig inhibits alloreactive CD8+ T cell proliferation and IFN-c production in vitro, in particular in
the absence of CD28 costimulation. Consequently CD160Ig prolongs fully mismatched cardiac allograft survival in CD42/2,
CD282/2 knockout and CTLA4Ig treated WT recipients, but not in WT or CD82/2 knockout recipients. The prolonged cardiac
allograft survival is associated with reduced alloreactive CD8+ T cell proliferation, effector/memory responses and
alloreactive IFN-c production. Thus, CD160 signaling is particularly important in CD28-independent effector/memory CD8+
alloreactive T cell activation in vivo and therefore may serve as a novel target for prevention of allograft rejection.
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Introduction
Full T cell activation in response to alloantigen presentation
requires, in addition to stimulation through the TCR, a
costimulatory signal [1]. One of the most widely studied positive
costimulatory signals is the CD28:B7 pathway. While CD28
blockade has been shown to prolong allograft survival in some
transplant models [2–6], less success has been observed in more
stringent models [7]. This process is thought to be mediated
predominantly by NK cells [8–9], CD8+ T cells [10–13] and
effector/memory responses [14], which appear to be less
dependent on CD28 costimulation, and might therefore utilize
alternative costimulatory pathways for activation [15].
CD160, is an immunoglobulin (Ig)-like glycosyl-phosphatidyli-
nositol (GPI)-anchored cell membrane receptor, which was first
identified in humans [16–18]. The murine expression of CD160 is
similar to that in humans and is largely restricted to cells with
cytolytic activity including NK cells, NKT cells and activated
CD8+ T cells [17,19–20]. Furthermore, CD160 is expressed by
growing endothelial cells and blocking its interaction with
endothelial cells using a human anti-CD160 mAb (CL1-R2) has
been shown to diminish angiogenesis without the need for Fc
receptor–bearing cytotoxic immune cells [21].
Both classical and non-classical MHC class-I molecules,
including CD1d, bind to CD160 with low affinity [16,19,22–23].
Recently HVEM was identified as the signaling ligand for CD160
[24]. CD160 binds HVEM in the CRD1 region [25] forming a
disulfide-linked interchain homotrimers [26] that can activate
HVEM signaling, and form a bidirectional signaling pathway [25].
Crosslinking murine CD160 enhances NK and T cell cytolytic
activity [16,22–23] and leads to the production of IFN-c, TNF-a
and IL-6 [22,27]. CD160 particularly stimulates CD8bright
cytotoxic effector lymphocytes lacking CD28 expression [16],
CD8+CD160+ memory T cells [20] and seems to deliver a potent
costimulatory signal to activated but not naı¨ve CD8 T cells [28].
However, engagement of CD160 on human CD4+ T cells by
HVEM has been shown to block LIGHT-HVEM induced
activation [24] and cross-linking of human CD160 with mAb
inhibit anti-CD3/anti-CD28-induced CD4 and CD8 T cell
activation profoundly [29]. However, the CD160-mediated
inhibition of human T cell proliferation has not been reproduced
in murine T cells using rat anti-mouse CD160 mAb [16,19,22–
23]. Furthermore, soluble CD160 blocks NK cell cytolytic activity
[26], while the CD160 transmembrane form has an activating role
in NK cells [30]. Thus, it seems that depending on the
extracellular domain of the CD160 protein that is involved in
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the interaction, a costimulatory or coinhibitory signal can be
transduced.
To date the role for the CD160:CD160L interaction in
alloimmune responses is undefined. Since ligation of CD160
triggers NK and CD8+ T cell activation and effector function, we
speculated that it might function as an alternative costimulatory
signal particularly in CD28-independent allograft rejection. Using
a novel fusion protein CD160Ig we demonstrate that blocking the
CD160:CD160L interaction prolongs fully mismatched heart
transplant survival in a model of CD28-independent CD8+
mediated allograft rejection by inhibiting alloreactive CD8+ T
cell proliferation, effector/memory expansion and cytokine
generation.
Materials and Methods
Mice
BALB/c (H-2d), B6.C-H2bm1/ByJ (H-2bm1) and C57BL/6 wild
type (WT), CD282/2, CD82/2 and CD42/2 knockout (KO)
mice (all H-2b) were purchased from The Jackson Laboratory. All
mice were used at 6–12 weeks of age.
Ethics Statement
Mice were housed in accordance with Institutional Animal Care
and Use Committee (IACUC) approval. All the experimental
procedures were performed in accordance with institutional and
National Institutes of Health guidelines and Institutional Animal
Care and Use Committee (IACUC) approval. The study was
carried out in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health. All surgery was performed using CO2
overdose euthanasia followed by thoracotomy, consistent with the
recommendations of the American Veterinary Medical Associa-
tion in accordance with Institutional Animal Care and Use
Committee (IACUC) approval and all efforts were made to
minimize suffering.
Murine Heart and Skin Transplantation
Heterotopic vascularized cardiac grafts from BALB/c donors
were transplanted using microsurgical techniques as described by
Corry et al. [31]. Graft function was monitored by daily palpation.
Rejection was defined as complete cessation of cardiac contrac-
tility.
Full-thickness trunk skin grafts from bm1 donors (,1 cm2) were
transplanted onto the dorsal thorax of recipient mice, sutured with
4-0 silk, secured with dry gauze and a bandage for 7 days. Skin
graft survival was monitored daily. Rejection was defined as
complete graft necrosis.
CD160 Fusion Protein
The murine CD160Ig fusion protein was made by linking the
complete extracellular domain of murine CD160 to the hinge-
CH2-CH3 domain of murine immunoglobulin G 2a (mIgG2a)
with four point mutations blocking Fc receptor and complement
binding. Briefly, the complete extracellular domain of murine
CD160 was amplified by PCR using a murine CD160 cDNA
(C57/BL6 AK042093) as template and forward primer 59-
GCTACGGGTACCACCATGCAAAGAATCCT-
GATGGCCCCTG and reverse primer, 59-GGCCCTTCCGGA-
GAGAGTGCCGTTGATATGGCTGAAG. The PCR product
was digested with Acc65I and BspEI and cloned into Acc65I,
BspEI digested mIgG2a-pEF6 vector. CHO-S cells were trans-
fected with the plasmid, selected for Blasticidin resistance,
subcloned, and screened for production by ELISA for mIgG2a.
The CD160-mIgG2a was purified from conditioned media by
protein A sepharose chromatography.
In vivo Treatment Protocol
Recipient mice were injected i.p. with CD160Ig or control Ig
(murine IgG2a) on day 0 (0.5 mg) and on days 2, 4, 6, 8, and 10
(0.25 mg). CTLA4Ig (Abatacept, Bristol Myers Squibb) was given
i.p on day 0 (0.5 mg) and on days 2, 4 and 6 (0.25 mg).
Rapamycin was a generous gift of Joren Madsen (TBRC,
Massachusetts General Hospital, Boston, Massachusetts, USA)
and was administered i.p at 0.3 mg/kg for day 0–3.
FACS Analysis
Splenocytes from WT and KO mice were obtained as single cell
suspension and stimulated with various concentrations of ConA
(0.1 and 1 mcg/ml) for 24. The percentage of CD160 expressing
naive as well as effector/memory CD4+ and CD8+ T cells,
characterized by a CD44highCD62Llow phenotype, was deter-
mined by flow cytometry. The percentages of effector/memory
CD4+ and CD8+ cells in recipient’s spleen were measured at
different time points. Flow cytometry was performed using a
FACSCalibur flow cytometry system (Beckton Dickinson, San
Jose, CA) and analyzed using CellQuest software (Beckton
Dickinson, San Jose, CA). All antibodies were obtained from BD
Pharmingen except of anti-CD160 PE (Clone BY55, Beckman
Coulter).
ELISPOT Assay
Splenocytes from recipient mice were obtained as single cell
suspension and stimulated with irradiated (30 Gy) syngeneic, or
allogeneic splenocytes (Balb/c). The technique for ELISPOT
analysis has been described by our group and others [32–33] and
was adapted to measure IFN-c, and IL-5 secreting cells. All
samples were tested in quadruplicate wells and frequencies are
expressed as the number of spot forming cells (SFC) per 0.56106
splenocytes.
Cytokine Analysis by LUMINEX Assay
The cell-free supernatants of the ELISPOT assay were
harvested after 48 h and analyzed by multiplexed cytokine bead-
based immunoassay using a 21-plex mouse cytokine detection kit
(Upstate) according to the manufacturer’s instructions. All samples
were tested in triplicate wells.
CFSE Labeling
Splenocytes and LN cells from WT or CD282/2 mice were
obtained as single cell suspension and stained with CFSE
(Molecular Probes, Portland, OR) as previously described [34].
Recipient BALB/c mice were sublethally irradiated (1000 rad)
with a Gammacell Exactor (Kanata, Ontario, Canada). Each
mouse received 6286107 CFSE-labeled donor cells i.v. and was
treated with CD160Ig or control Ig on day 0 and 2 (0.5 mg).
Three days later, the in vivo proliferation of CFSE-labeled donor
cells was evaluated by flow cytometric analysis and the responder
frequency was calculated as previously reported [34]. The large
number of cells transferred (6286107 cells/mouse) and the time
point examined (3 days) preclude homeostatic expansion of CFSE-
labeled cells in the irradiated hosts, and cell division in this model
is driven primarily by the host alloantigens [35].
Statistics
Kaplan-Meier survival graphs were constructed and a log rank
comparison of the groups was used to calculate p values. Student’s
Role of CD160-CD160L in Allo-Immunity
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t test was used for comparison of means between experimental
groups examined by FACS analysis or ELISPOT assay. Differ-
ences were considered to be significant at p values ,0.05.
Results
Similar Expression Patterns of CD160 Receptor in WT and
KO Mice
To characterize the expression of CD160, we stained spleno-
cytes obtained form naı¨ve WT and knockout (KO) mice with anti-
CD160. Low level expression of CD160 was noted on both CD4+
and CD8+ T cells (2.861.3% and 2.361.8% respectively) as well
as on NK cells (1.960.1%). To determine whether the expression
of CD160 varies with the activation status of T cells we stimulated
splenocytes with ConA in vitro. Subsequently, CD160 expression
on CD4+ and CD8+ T cells, characterized by an effector/memory
phenotype (CD44highCD62Llow), was determined. We found that
expression of CD160 was significantly upregulated on both
CD4+CD44highCD62Llow (9.560.3%) and to a higher degree
CD8+CD44highCD62Llow effector/memory T cells (14.561.5%),
suggesting that CD160 expression is particularly induced after
CD8+ T cell activation. Of notice, the expression pattern of
CD160 did not differ between the WT mice and KO animals
(Figure 1).
Decreases Alloreactive T Cell Proliferation and IFN-c
Production
To investigate the function of CD160, we generated a murine
CD160Ig fusion protein, as described in the methods section. First
we evaluated its role in alloreactive T cell proliferation in vitro.
Since CD160 is upregulated after T cell activation we used
splenocytes from sensitized WT and KO recipient mice, who had
received a prior skin allograft from BALB/c mice. Splenocytes
were stimulated with irradiated donor splenocytes (BALB/c) in the
presence of increasing concentrations of CD160Ig or control Ig.
Cell proliferation was measured by (3H)thymidine incorporation.
As expected T cell proliferation was significantly reduced in
CD42/2 (2471563990 cpm, n = 12; p = 0.0012), CD82/2
(2596463926 cpm, n = 12; p = 0.014), and CD282/2 mice
(1617662676 cpm, n = 12; p,0.0001) as compared to WT mice
(3263363097 cpm, n = 12). CD160Ig strongly inhibited prolifer-
ation of both CD4+ and CD8+ T cells in a dose dependent
manner. However, the inhibitory effect of CD160Ig was indepen-
dent of CD28 costimulation, in that the proliferation of T cells
from WT, CD42/2 and CD82/2 recipients was reduced to a
similar degree as from CD282/2 recipients (Figure 2A).
We then assessed the effect of CD160Ig on alloreactive IFN-c
production using an ELISPOT assay in the same culture
conditions. Again IFN-c-production was significantly reduced in
CD42/2 (190.9613.7 spot forming cells (SFC), n = 12;
p,0.0001), CD82/2 (232.2623.25 SFC, n = 12; p = 0.004), and
CD282/2 mice (198.2635.42 SFC, n = 12; p = 0.0023) as
compared to WT mice (414639.25 SFC, n = 12). CD160Ig
inhibited the alloreactive IFN-c production moderately in a dose
dependent manner in WT splenocytes (7, 15 and 17% respec-
tively). Interestingly, its inhibitory effect was more pronounced in
CD8+ than in CD4+ T cells, in that the maximal reduction in IFN-
c production was 60% in CD42/2 (vs. WT; p,0.05) as compared
to 46% in CD82/2 recipients (vs. WT; ns). Notably, in the
absence of CD28 costimulation we observed the maximal
inhibition (.70%) of alloreactive IFN-c production (vs. WT;
p,0.0001) (Figure 2B and C).
CD160Ig Prolongs Cardiac Allograft Survival in CD282/2
and CD42/2 Recipients
To delineate the role of the CD160:CD160L pathway in vivo we
transplanted vascularized cardiac grafts from BALB/c donors into
fully allogeneic WT and KO recipients which were treated with
CD160Ig or control Ig. CD160Ig treatment had an insignificant
effect on graft survival in WT (median survival time (MST) = 10
vs. 7 days, n = 5, ns, Figure 3A) and in CD82/2 recipients
(MST = 12 vs. 12 days, n = 5, ns, Figure 3B), while CD8+ T cell-
mediated allograft rejection in CD42/2 mice was significantly
delayed (MST = 56 vs. 34 days, n = 5, p = 0.01, Figure 3C). In
keeping with the in vitro data, CD160Ig treatment led to a striking
prolongation in allograft survival in CD282/2 mice (MST = 12 vs.
30 days, n = 5; p = 0.002) as shown in Figure 3D. To confirm these
results in a more physiological context we went on and used
CTLA4Ig in combination with CD160Ig in WT recipients.
Indeed, combined treatment prolonged allograft survival to a
greater extend as compared to CTLA4Ig treatment alone
(MST = 44.5 vs. 24 days, Figure 3E).
To confirm the impact of CD160Ig on CD8+ T cell responses
in vivo we studied its role in a MHC class I miss-matched skin
allograft model (bm1 into B6), in which rejection is predominantly
driven by CD8+ T cells. In accordance with its effect in CD42/2
heart transplant recipients CD160Ig significantly prolonged skin
allograft survival (MST = 18 vs. 13 days, n = 5; p,0.003),
(Figure 3F).
CD160Ig Inhibits IFN-c and Promotes IL-5 Alloreactive
Cytokine Production in CD282/2 and CD42/2 Recipients
Given our in vitro and survival data we reasoned, that CD160Ig
may prolong allograft survival in KO recipients by blocking the
generation and/or function of alloreactive cytokine production
in vivo. In order to explore this possibility, we measured the
frequency of IFN-c and IL-5 alloreactive T cells in WT, CD42/2
and CD282/2 recipients by ELISPOT assay. As shown in
Figure 4A the frequency of alloreactive IFN-c-producing T cells
did not differ between CD160Ig treated and control Ig treated WT
recipients (393658 vs. 410644 SFC, n = 12; ns). However, we
noted a significant increase in the frequency of alloreactive IL-5
generating T cells (5266.2 vs. 1761.4 SFC; p.0.0005). Interest-
ingly, the enhanced allograft survival in CD282/2 recipients
treated with CD160Ig or in WT recipients treated with a
combination of CTLA4Ig and CD160Ig was associated with a
robust reduction in the frequency of IFN-c secreting alloreactive T
cells (CD282/2: 170620 vs. 368630 SFC, n = 30; p,0.0001;
CTLA4Ig treated WT: 5663 vs. 125613 SFC, n = 20;
p,0.0001), while the frequency of alloreactive IL-5 secreting T
cells significantly increased (CD282/2 recipients: 8167 vs. 3665
SFC; p,0.0001; CTLA4Ig treated WT: 562 vs. 2262 SFC;
p,0.0001). The same observation was true for CD42/2 recipients
after CD160Ig treatment (IFN-c: 3363 vs. 6765 SFC; n = 20,
p,0.0001, IL-5:484659 vs. 162622; p,0.0001) indicating that
prolongation of cardiac allograft survival with CD160Ig is
associated with a switch in the cytokine profile of alloreactive T
cells (Figure 4A).
Because crosslinking of CD160 has been shown to enhance the
production of the cytokines IFN-c, TNF-a and IL-6 [22–23] we
studied the effect of CD160Ig on the production of these cytokines
by Luminex Assay in CD282/2 recipients. Confirming the results
observed with the ELISPOT assay, CD160Ig treatment signifi-
cantly inhibited IFN-c, TNF-a, IL-6 and IL-17 production, while
it increased the production of IL-4 and IL-5 (Figure 4B).
Role of CD160-CD160L in Allo-Immunity
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CD160Ig Inhibits CD8+ Effector/Memory Cell Expansion in
CD282/2 Recipients
To assess the effect of CD160Ig on generation effector/memory
T cells we measured the percentage of CD4+ and CD8+ T cells
manifesting a effector/memory phenotype (CD62LlowCD44high) in
WT, CD42/2 and CD282/2 recipients. In keeping with the
ELISPOT data, no significant reduction in either CD4+ or CD8+
effector/memory T cells was observed in CD160Ig treated WT
recipients. Interestingly, CD160Ig treatment did not alter the
frequency of effector/memory CD8+ T cells in CD42/2 recipients
(5.1610660.46106 cells vs. 5.4610660.26106 cells n = 5, ns)
despite the significant reduction in the frequency of alloreactive
IFN-c production. In contrast, the frequency of effector/memory
CD8+ T cells was significantly reduced in CD160Ig treated
CD282/2 recipients (8.9610661.56106 cells vs.
5.7610660.86106%, n = 5, p,0.0001) as well as in CD160Ig
plus CTLA4Ig treated WT recipients (11610661.56106cells vs.
7610660.36106cells, n = 4, p,0.05) (Figure 5), while the
frequency of effector/memory CD4+ T cells was not affected.
Furthermore, no effect of CD160Ig on NK cells could be observed
in any group as assessed by quantification of the total NK
(NK1.1+CD32CD122+) cell numbers in various lymphoid organs
of recipient mice and the expression of various activation (CD25
and CD69) or adhesion molecules (CD44) on NK cells by FACS
analysis.
Figure 1. CD160 is expressed on CD8 and CD4 T cells. Naı¨ve or stimulated (ConA) splenocytes from wildtype C57BL/6 (WT), CD42/2, CD82/2
and CD282/2 mice were stained with anti-CD160. Mean fluorescence intensity of CD160 on naı¨ve CD8+ and CD4+ T cells or CD8+ and CD4+ T cells
expressing an effector/memory phenotype (CD44highCD62Llow) was analyzed. Upper Panel: Representative dot plots of CD160 expressing cells
(shaded histograms) in WT mice. Lower Panel: The histograms demonstrate the MFI of CD160+ cells of the overall CD4+ or CD8+ T cell population as
the mean 6 SEM of 3–5 independent experiments.
doi:10.1371/journal.pone.0060391.g001
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CD160Ig does not Alter Expression of CD160 or MHC
Class I on APCs
Recently HVEM was identified as the signaling ligand for
CD160 [24]. However, CD160 has been shown to bind both
classical and non-classical MHC class-I molecules with low affinity
[16,19,22–23]. Therefore, we examined the level of expression of
MHC class I molecule on the surface of CD19+ B cells, CD11c+
dentritic cells and CD11b+ monocytes derived from naı¨ve, as well
as CD160Ig treated and control Ig treated WT and KO mice at
baseline and time of rejection. As expected, flow cytometry
analysis revealed that MHC class I was expressed by naı¨ve B cells,
dentritic cells and monocytes and the level of expression
significantly increased during the alloresponse as compared to
baseline on all three cell types (data not shown). Importantly,
MHC class I molecule expression did not differ between WT and
the various KO mice at any time point excluding, that a limited
amount of antigen and/or low level of TCR/pMHC interaction
during the alloresponse was the reason for the observed differences
in allograft survival between the groups. Furthermore, we were
unable to observe marked differences in the MHC class I
expression between CD160Ig and control Ig treated recipients
(Figure S1).
CD160Ig does not Alter Cytolytic Activity of CD8+ T Cells
and NK Cells in CD282/2 Recipients
Previous studies have shown, that CD160 enhances the cytolytic
activity of CD8+ T cells and NK cells [16,22–23]. Therefore, we
examined the effect of CD160Ig on cytotoxic cell subsets in vivo by
measuring the frequency of GranzymeB producing alloreactive
cells by ELISPOT in WT, CD42/2 and CD282/2 recipients.
However, CD160Ig treatment had an insignificant effect on
alloreactive GranzymeB production in all groups suggesting, that
CD160Ig did not influence cytolytic activity of CD8+ T cells and
NK cells (data not shown).
CD160Ig Reduces Alloreactive CD8+ T Cell Proliferation
in vivo in the Absence of CD28
The expansion of alloreactive T cell clone size is a key event in
initiation of the rejection process. To examine the impact of
CD160Ig on T cell proliferation in vivo CFSE labeled leucocytes
from either WT or CD282/2 mice were adoptively transferred
Figure 2. CD160Ig inhibits allospecific T cell proliferation and Th1 cytokine generation. Wildtype C57BL/6 (WT), CD42/2, CD82/2 and
CD282/2 mice (all H-2b) were sensitized with skins from fully missmatched BALB/c (H-2d) donors. Recipients splenocytes were harvested and cultured
with irradiated donor splenocytes in the absence and in the presence of increasing concentrations of CD160Ig or control Ig. A) Cell proliferation is
expressed as percent inhibition of CD160Ig treated cells compared with control Ig treated cells of that strain. Results are presented as the mean 6
SEM of 3 experiments performed in triplicates. B) Frequency of alloreactive IFN-c producing cells was quantified by ELISPOT assay after 24 hours.
Percent inhibition of IFN-c production of CD160Ig treated cells compared with control Ig treated cells of that strain is shown. Results shown are mean
6 SEM values of 3 independent experiments performed in quadruplicate wells. C.) Statistics of percent inhibition of alloreactive IFN-c production at
100 mg/ml CD160Ig/well.
doi:10.1371/journal.pone.0060391.g002
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Figure 3. CD160Ig prolongs fully mismatched heart allograft survival in CD282/2 and CD42/2mice. A) C57BL/6 WT (n = 10); B) CD42/2,
(n = 10); C) CD82/2 (n = 10); D) CD282/2 (n = 10) or E) C57BL/6 WT treated with CTLA4-Ig (n = 5) received Balb/c heart grafts and were treated with
CD160Ig (X; n = 5) or control Ig (%; n = 5); F) C57BL/6 WT (n = 5) received bm1 skin grafts and were treated with CD160Ig (X, n = 5) or control-Ig (%;
n = 5); Survival is shown by Kaplan-Meier plots.
doi:10.1371/journal.pone.0060391.g003
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into irradiated allogeneic BALB/c hosts and CD4+ and CD8+ T
cell proliferation was assessed by FACS analysis 3 days thereafter.
In the presence of CD28 costimulation, CD160Ig did not inhibit
the in vivo proliferation of CD4+ (30.164.4 vs. 3064% precursor
division frequency (PDF), n = 5) and CD8+ T cells (2861.4 vs.
27.462.2% PDF, n = 4). However, CD160Ig significantly reduced
the in vivo proliferation of CD28 deficient CD8+ T cells (2663.8
vs. 1962.7% PDF, n = 5, p = 0.01) and, although to a lesser
degree, that of CD28 deficient CD4+ T cells (1762.2 vs.
14.761.7% PDF, n = 5, p = 0.04) (Figure 6).
Clinical Relevance
Rapamycin has been reported to synergize with a variety of
strategies targeting T cell costimulatory pathways [31,36]. To
study the clinical relevance of CD160Ig we evaluated its effect in
the combination with a subtherapeutic dose of rapamycin in WT
recipients. While CD160Ig alone had no effect on allograft
survival in WT recipients, subtherapeutic doses of rapamycin
resulted in a moderate prolongation of allograft survival in WT
mice (MST 29 vs. 7 days, n = 5; p,0.002). However, combination
of both resulted in synergistic prolongation of allograft survival
(MST 46 days, n = 5; p,0.001) not seen with either agent alone.
The prolonged allograft survival after rapamycin treatment was
associated with a significant reduction in the alloreactive Th1
cytokine production, as assessed by IFN-c ELISPOT, and
generation of effector/memory CD8+ T cells. However, the
addition of CD160Ig did not further reduce the alloreactive Th1
effector response, but significantly enhanced the number of
alloreactive IL-4 and IL-5 producing cells, indicating again, that
CD160Ig is associated with a marked Th2 switch in the cytokine
profile of alloreactive T cells (Figure S2).
Figure 4. CD160Ig reduces allospecific Th1 cytokine generation in CD282/2 and CD42/2 mice. Heart grafts from BALB/c donors were
transplanted into C57BL/6 WT, CD282/2 or CD42/2 recipients, which were treated with CD160Ig +/2 CTLA4Ig or control Ig. Recipient splenocytes
were isolated 10 days (WT recipients) or 14 days (CD282/2 and CD42/2 recipients, CTLA4Ig treated WT recipients) after transplantation, cultured with
irradiated donor splenocytes. A) The frequency of alloreactive IFN-c and IL-5 producing T cells was analyzed by ELISPOT. B). The concentration of TNF-
a, IL-6, IFN-c, IL-17, IL-4 and IL-5 was examined by Luminex Assay in the supernatants of the cultures with CD282/2 responder cells. The data shown
are pooled from 3–5 independent experiments performed in quadruplicate wells (Mean6SEM).
doi:10.1371/journal.pone.0060391.g004
Figure 5. CD160Ig reduces effector/memory cell generation in CD282/2 mice. Splenocytes from C57BL/6 WT, C57BL/6 WT treated with
CTLA4Ig or CD282/2 recipients of BALB/c hearts were harvested and CD4+ or CD8+ T cells were stained for the effector/memory phenotype,
characterized as CD44highCD62Llow. Left Panel: Representative dot plots of CD8+CD44highCD62Llow cells. Right Panel: The histograms demonstrate
the frequency of CD44highCD62Llow cells as a percentage of the overall CD4+ or CD8+ T cell population as the mean 6 SEM of 3–5 independent
experiments.
doi:10.1371/journal.pone.0060391.g005
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Discussion
This is the first study establishing the in vivo function of the novel
T cell costimulatory pathway CD160:CD160L in alloimmune
responses. Our data clearly demonstrate that the CD160:CD160L
pathway plays an important role in CD28-independent CD8+ T
cell alloimmune responses. CD160 is expressed on a small
percentage of CD4+ and CD8+ T cells and is predominantly
upregulated after CD8+ T cell activation. CD160Ig inhibits the
alloreactive T cell proliferation and IFN-c production in vitro with
the most profound effect on CD8+ T cells and lymphocytes lacking
CD28 expression. CD160Ig consequently prolongs allograft
survival in CD42/2, CD282/2 as well as CTLA4Ig treated WT
recipients. The prolongation in allograft survival is associated with
reduced alloreactive CD8+ T cell proliferation, diminished
generation of effector/memory CD8+ T cells and switch in the
cytokine profile of alloreactive T cells. Interestingly, CD4+ T cell
functions appear to be relatively insensitive to the effects of
CD160Ig in vivo in our model.
It is well recognized that blocking the CD28:B7 costimulatory
pathway is effective in inducing tolerance in some rodent models
[2–6], but is not sufficient to block transplant rejection in more
stringent models [7]. Effector/memory responses [14] and/or
CD8+ T cell responses [10–13] appear to be less dependent on
CD28 costimulation and represent a significant barrier to the
development of tolerance to alloantigen [14,37]. Our results
establish an important role for CD160:CD160L pathway in CD8+
effector/memory T cell responses in vivo, especially in the absence
of CD28 costimulation, as seen by the suppressed alloreactive IFN-
c cytokine generation and contraction in the size of the effector/
memory cell population (CD44hiCD62Llow) of CD8+ T cells.
These data are in keeping with previously published findings that
expression of murine CD160 is largely restricted to cytotoxic NK
cells and a subset of cytotoxic CD8bright+ T cells [17–18,38] as well
as CD8+ effector/memory T cells [19–20]. Furthermore, CD160
has been shown to act as a co-receptor in TCR signal transduction
in CD8+ T cells [28] leading to the expansion of CD282 T
lymphocytes [16,28,38].
Recent data indicate that the membrane-bound CD160
molecule can be cleaved from the cell surface upon activation
and released as a soluble form (sCD160) which serves to limit
CD8+ effector functions by binding to MHC class-I on target cells
in situ. This provides a physiological mechanism to control CD8+
CTL activity [20,26]. sCD160 mediated down-modulation of
cytolytic activity is not restricted to cytotoxic T cell clones, but is
also effective on allogeneic stimulated T cells [26]. However, in
our study CD160Ig inhibited alloreactive CD8+ T lymphocyte
proliferation and IFN-c production but did not alter the cytolytic
activity. However, CD160 mRNA expression has been demon-
strated on exhausted CD8 T cells in the late stage of chronic viral
infection, which coincides with loss of CTL function [39–41].
Thus the effect of CD160Ig seen in our model might be the result
of blocking a co-stimulatory signal in late stage differentiated
CD8+ T cells, leading to a diminished proliferation, expansion
and differentiation rather than affecting their cytotoxic capacity.
The mechanism by which CD160Ig prolongs allograft survival
could also be due to both reduction in pro-inflammatory T cells
(alloreactive IFN-c cells) and induction of anti-inflammatory
alloreactive IL-5 cells, which would be in agreement with several
studies showing that tolerance induction by costimulatory block-
ade is sometimes associated with a state of ‘‘immune deviation’’
toward Th2 cell function [5]. However, whether a Th2 switch per
se can mediate transplant tolerance remains controversial [42].
The effect of Th2 deviation in promoting graft survival seems to
depend on the alloreactive T cell clone size [43–44], as shown
after CD160Ig treatment.
However, it is increasingly recognized, that active regulation to
maintain self-tolerance and prevent alloimmune responses is not
only due to CD4+ regulatory T cells (Tregs), but is also dependent
on the presence of CD8+ Tregs [45]. Among others CD8+CD282
Tregs have been described both in humans and CD282/2 mice
[46–48]. Recent evidence indicates a potentially important
relationship between immune modulatory Th2 cytokines and
Figure 6. CD160Ig decreases in vivo proliferation of CD28 deficient CD8+ T cells. CFSE-labeled splenocytes from C57BL/6 WT, CD82/2,
CD42/2 or CD282/2 mice (6286107) were injected into irradiated BALB/c hosts and treated with CD160Ig or control Ig. The precursor division
frequency of CD4+ and CD8+ T cell subsets in the host spleen was analyzed 3 days later by FACS and calculated as described in Materials and
Methods. Representative histograms from one of 3 experiments are shown.
doi:10.1371/journal.pone.0060391.g006
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Tregs. The more pronounced effect of CD160Ig in the absence of
CD28 costimulation might therefore be due to an enhanced active
regulation.
Despite the inherent complexity of the costimulatory pathway
interactions, selective blockade of individual molecules remains an
attractive target as part of a multifaceted approach, as the phase II
clinical study using CTLA4Ig in renal transplant recipients
successfully showed [49]. Combination therapy of costimulatory
blockade with CTLA4-Ig, MR1 [50] or rapamycin [51] has been
shown to prolong graft survival. In the current study, we
demonstrate the synergistic effect of CD160Ig when combined
with rapamycin and CTLA4-Ig in prolonging allograft survival.
We anticipate that targeting the CD160:CD160L pathway in
combination with theses reagents may provide clinical benefits
through their role as part of a less toxic maintenance strategy.
In conclusion, CD160 signaling is particularly critical for CD28-
independent effector/memory CD8+ alloreactive T cell activation
in vivo and therefore the novel fusion protein, CD160Ig, may prove
to be a promising reagent in strategies for prevention of allograft
rejection in conjunction with B7/CD154 T cell costimulatory
blockade.
Supporting Information
Figure S1 CD160Ig has no effect on MHC class I expression. A)
CD11c+ dentritic cells from naı¨ve WT, CD42/2, CD82/2 and
CD282/2 mice were stained for the expression of MHC class I
molecules. B) CD11c+ dentritic cells from CD282/2 recipients of
BALB/c hearts were stained for the expression of MHC class I
molecules at baseline (day 0) and on day 14 and 30 (time point of
rejection) in treated and untreated recipients. The histograms
demonstrate the frequency MHC class I positive cells as a
percentage of the overall CD11c+ T cell population as the mean6
SEM of 3–5 independent experiments.
(TIF)
Figure S2 CD160Ig in combination with rapamycin prolongs
fully mismatched heart allograft survival WT mice. C57BL/6 WT
(n = 5) mice received Balb/c heart grafts and were treated with
CD160Ig +/2 subtherapeutic dosis of rapamycin (0.3 mg/kg for
days 0–3) as described in Materials and Methods. A) Kaplan-
Meier plots demonstrate allograft survival B) The histogram
demonstrates the frequency of CD44highCD62Llow cells as a
percentage of the overall CD8+ T cell population isolated on day
14 after transplantation as the mean 6 SEM of 3–5 independent
experiments. C - E) The histograms demonstrate the alloreactive
IFN-c (C), IL-4 (D) and IL-5 (E) production, as assessed by
ELISPOT on day 14 as the mean 6 SEM of 3–5 independent
experiments.
(TIF)
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